Tegileridine Patient-Controlled Intravenous Analgesia for Postoperative Respiratory Function and Analgesic Efficacy in OSA and Obese Patients Undergoing Major Abdominal Surgery: A Randomized, Prospective, Multicenter Study

Start Date20 Feb 2026

Sponsor / Collaborator

Shaoxing People's Hospital

NCT07395596

/ RecruitingPhase 4IIT

A Prospective, Randomized Controlled Clinical Study of the Effect of Remimazolam on the Incidence of Hypoxia in High-risk Patients Undergoing Painless Tracheoscopy

Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient, making the patient highly susceptible to respiratory and cardiovascular risks. Among these risks, hypoxia is the most common adverse event.Different drug regimens can be selected for anesthesia under deep sedation. The combination of analgesic agents can help reduce coughing during bronchoscopy. Therefore, we employ a combination of sedative and analgesic drugs for painless bronchoscopy procedures. Among sedatives, propofol is the most commonly used. However, due to its disadvantages, such as respiratory and circulatory depression, we have introduced a novel approach combining remimazolam for sedation. The aim is to investigate whether this new regimen, compared to traditional propofol-based sedation, can reduce the incidence of hypoxia, minimize circulatory depression, and lead to faster postoperative awakening and recovery. Additionally, we hope to observe fewer adverse events, such as perioperative nausea and vomiting, excessive secretions, dizziness, and chills.

Start Date09 Feb 2026

Sponsor / Collaborator

The First Affiliated Hospital, Zhejiang University Sch of Med

[+1]

ChiCTR2600116113

/ Not yet recruitingNot ApplicableIIT

A study on the relationship among shift nurses' emotional regulation difficulties, hedonic hunger, and food addiction from the perspective of social jetlag

Start Date01 Jan 2026

Sponsor / Collaborator

Shaoxing People's Hospital

100 Clinical Results associated with Shaoxing People's Hospital

0 Patents (Medical) associated with Shaoxing People's Hospital

1,091

Literatures (Medical) associated with Shaoxing People's Hospital

01 Feb 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Efficacy of HFNC + NIV as initial oxygen therapy in acute respiratory failure: Meta-analysis

Review

Author: Liu, Weidong ; Li, Shunfa ; Guo, Haiying ; Zhou, Yaoying ; Wang, Weizhong ; Xu, Ting ; Zhang, Pan

BACKGROUND:

Combining non-invasive ventilation (NIV) and high-flow nasal cannula (HFNC) may offer complementary benefits in acute respiratory failure (ARF). Prior meta-analyses compared monotherapies or post-extubation combination therapy, but none specifically evaluated NIV + HFNC as the initial strategy to prevent intubation or mortality.

OBJECTIVES:

To compare the efficacy of initial NIV + HFNC versus NIV or HFNC monotherapy for preventing intubation and mortality in adults with ARF.

METHODS:

We systematically searched PubMed, Embase, Cochrane Library, and Web of Science (inception to May 31, 2025) for relevant RCTs. Primary outcome was intubation rate; secondary outcome was mortality. Statistical data analysis was performed using RevMan software. Risk of bias was assessed (Cochrane RoB 2).

RESULTS:

Six RCTs (N = 764 participants) were included. Compared with monotherapy, combined NIV + HFNC did not significantly affect intubation rates (OR 1.08, 95 % CI 0.79-1.49; P = 0.62; I² = 23 %) or mortality (OR 1.41, 95 % CI 0.60-3.34; P = 0.43; I² = 62 %). Subgroup analyses by control intervention (NIV alone or HFNC alone) and trial design (single-center vs. multi-center) also showed no statistically significant differences. Notably, the largest studies exhibited contrasting trends, potentially attributable to variations in lung-protective ventilation strategies during NIV.

CONCLUSIONS:

This meta-analysis found no significant benefit of initial NIV + HFNC over monotherapy in reducing intubation or mortality in ARF. Future high-quality RCTs should prioritize standardized protocols, explicit lung-protective NIV settings, and larger sample sizes, with particular emphasis on specific ARF phenotypes that may derive maximal benefit from combined therapy.

01 Feb 2026·TISSUE & CELL

Ginsenoside Rg3 alleviates allergic rhinitis by regulating NLRP3-mediated inflammatory response and pyroptosis through SIRT6

Article

Author: Wang, Fang ; Wang, Wei

BACKGROUND:

Allergic rhinitis (AR) is positively correlated with pyroptosis induced by NLR family pyrin domain containing 3 (NLRP3). Here, the effect of ginsenoside Rg3 on pyroptosis in the progression of AR was evaluated.

METHODS:

Human nasal epithelial cells (HNEPCs) were exposed to house dust mite (HDM) allergen to establish an AR cell model. Cell viability and pyroptosis were tested utilizing CCK-8 and flow cytometry. RT-qPCR and Western blot were used to detect mRNA and protein expression. Co-immunoprecipitation (Co-IP) assay was adopted to validate the molecular interaction. IgE, IL-4, IL-5, IL-13, IL-1β and IL-18 were detected by ELISA. AR mouse model was established using OVA and aluminum hydroxide. The sneezing frequency and nose rubbing frequency of mice were evaluated. HE staining was used to evaluate the pathological changes of nasal mucosa. Pyroptosis was detected by TUNEL and GSDMD staining.

RESULTS:

Ginsenoside Rg3 blocked NLRP3 inflammasome activation and pyroptosis induced by HDM allergen in HNEPCs, and increased cell activity inhibited by HDM. SIRT6 depletion overturned the suppressive effect of ginsenoside Rg3 on HDM-caused inflammation and pyroptosis in HNEPCs. Blocking SIRT6 diminished ginsenoside Rg3's protective role against sneezing and rubbing nose, inflammation and pyroptosis in AR mice. Furthermore, Co-IP assay confirmed that SIRT6 interacted with NLRP3 protein in HNEPCs. SIRT6 overexpression could decrease NLRP3 acetylation level and reduce NLRP3 expression.

CONCLUSION:

Our results reveal that ginsenoside Rg3 mitigates AR by controlling NLRP3-triggered inflammatory response and pyroptosis via SIRT6, which provides a new therapeutic strategy for AR treatment.

01 Feb 2026·iScience

Advances in mitochondrial-targeted colorectal cancer therapy: Mechanistic insights and clinical translation

Review

Author: Xu, Ling ; Zhang, Song-Ou ; Li, Zhen-Jun ; Du, Yang-Bing ; Che, Hao ; Ying, Xiao-Jiang

Colorectal cancer (CRC) therapy is challenged by drug resistance and limited treatment efficacy. Mounting evidence now positions mitochondrial dysfunction as a central mediator of these challenges, making it a compelling therapeutic target. This review synthesizes findings demonstrating that targeting mitochondrial metabolism, apoptosis, dynamics, mitophagy, and intercellular transfer effectively overcomes chemoresistance and restores treatment sensitivity in CRC models. Key mechanisms include the reversal of the Warburg effect, reactivation of intrinsic apoptosis, and disruption of mitochondrial transfer. Clinically, mitochondrial-derived biomarkers, such as cell-free mtDNA, emerge as promising tools for non-invasive monitoring and prognosis. Furthermore, advancements in targeted delivery systems and supportive interventions such as exercise, are shown to enhance therapeutic efficacy and mitigate toxicity. We conclude that integrating mitochondrial-targeted strategies represents a transformative approach for CRC treatment, with future success hinging on overcoming delivery challenges and validating these strategies in personalized models.

News (Medical) associated with Shaoxing People's Hospital

26 Jan 2026

·www.drugs.com

Odds of Overactive Bladder Elevated Among Patients With Diabetes

MONDAY, Jan. 26, 2026 -- The prevalence of overactive bladder (OAB) is elevated among adults with diabetes , with significant risk factors including age, diabetes duration, hypertension , and neuropathy, according to a review published online Jan. 11 in Neurology and Urodynamics . Xiaolong Zhang, from the Shaoxing People's Hospital in China, and colleagues conducted a systematic review and meta-analysis to examine the pooled prevalence and potential risk factors for OAB in patients with diabetes. Fourteen studies from 2010 to 2024 were included for qualitative and quantitative analyses; the studies included 82,646 adult patients with diabetes. The researchers found that among patients with diabetes, the pooled prevalence of OAB was 30.3 percent, and the odds of OAB were significantly higher for patients with diabetes versus healthy controls (odds ratio, 3.566). In patients with diabetes, age, diabetes duration, hypertension, and neuropathy were identified as significant risk factors for OAB (odds ratios, 1.03, 1.57, 1.66, and 2.42, respectively). "These findings are crucial for public health, guiding effective interventions to mitigate OAB risk in diabetic patients," the authors write. Abstract/Full Text (subscription or payment may be required)

Clinical Result

100 Deals associated with Shaoxing People's Hospital

100 Translational Medicine associated with Shaoxing People's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bavachalcone ( TfR1 )	Parkinson Disease More	Preclinical
Hederagenin ( DENR x HK2 x PINK1 x PRKN x VDAC1 )	Pancreatic Cancer More	Preclinical
Farrerol ( MicroRNA MIR29 family x SIRT1 )	Diabetic Cardiomyopathies More	Preclinical
EccMIR3142 ( CFL1 x LIMK x MAPK )	Breast Cancer More	Preclinical
EccMIR6508 ( CFL1 x LIMK x MAPK )	Breast Cancer More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis